Saracatinib is an Src inhibitor that suppresses gastric cancer invasion and migration, which can also enhance the antitumor effects of lapatinib (Bertotti et al., 2010; Nam et al., 2013; Yamaguchi et al., 2014). Here, SRC is linked to gastric cancer.